GlaxoSmithKline
FREE Daily Email Newsletter
Drugmakers, Health Groups Bring Poor Girls Vaccine
May 9, 2013 7:58 am | by LINDA A. JOHNSON,AP Business Writer | News | CommentsTwo multinational drugmakers are teaming up with top global health groups to protect millions of girls in the world's poorest countries from deadly cervical cancer. Starting with pilot programs in eight Asian and African nations, the ambitious project ultimately is intended to inoculate more than 30 million girls in more than 40 countries by 2020.
UK Alleges GSK Paid Off Competitors to Delay Drugs
April 19, 2013 8:11 am | News | CommentsBritain's competition watchdog has accused GlaxoSmithKline of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat. The Office of Fair Trading alleges GlaxoSmithKline concluded agreements which infringed competition law with Alpharma Limited, Generics (UK) Ltd and Norton Healthcare Ltd. over the supply of paroxetine, a cheaper version of Seroxat.
FDA Panel Backs Inhaler Drug for Lung Disease
April 17, 2013 4:14 pm | by The Associated Press | News | CommentsA panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of Food and Drug Administration panelists voted that the Breo Ellipta inhaler is safe and effective for long-term use...
Glaxo, Theravance Rise on FDA Review of Lung Drug
April 15, 2013 1:26 pm | News | CommentsShares of Theravance and partner GlaxoSmithKline jumped today after the Food and Drug Administration posted its review of the companies' combination inhaler drug to treat lung disease. Glaxo and Theravance have asked the FDA to approve their experimental inhaler drug, Breo Ellipta, to treat complications of chronic lung disease.
FDA Reviewing Heart Risks of Glaxo Diabetes Pill
April 12, 2013 5:16 pm | by MATTHEW PERRONE - AP Health Writer - Associated Press | News | CommentsThe Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster drug Avandia, which was severely restricted in 2010 due to concerns about its impact on the heart. Regulators announced the highly unusual move in a government notice...
XenoPort Hits Supply Trouble for Drug Horizant
April 12, 2013 9:47 am | News | CommentsXenoPort Inc. said today that it has run into supply problems for its restless legs syndrome treatment Horizant. The company said it's received word from patients unable to fill their Horizant prescriptions. XenoPort hopes that a new stock of Horizant will be in pharmacies in June, but the timing is uncertain.
Eddingpharm Signs Collaboration Agreement with GlaxoSmithKline China for Novel Breast Cancer Drug
April 9, 2013 8:13 am | News | CommentsEddingpharm a specialty pharmaceutical company based in China, has announced that the company has entered into a collaboration agreement with GSK, whereby Eddingpharm will acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb, a treatment for advanced or metastatic breast cancer that was recently approved by the SFDA.
Former GSK Exec Joins BD
March 13, 2013 8:24 am | News | CommentsBD (Becton, Dickinson and Company) today announced the appointment of Ellen Strahlman, M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senior Vice President, Research & Development, effective April 22, 2013. Dr. Strahlman will report to Chairman, CEO and President Vincent A. Forlenza and will serve as a member of the Company's Management Committee and Leadership Team.
Drugmakers, Interpol Ramp Up Fight Against Fakes
March 12, 2013 1:01 am | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | CommentsMore than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
Glaxo Donates NC Wyeth Painting to Philly Museum
March 5, 2013 2:02 pm | by JOANN LOVIGLIO - Associated Press - Associated Press | News | CommentsPharmaceutical giant GlaxoSmithKline PLC has donated a painting with a mysterious past to the Philadelphia Museum of Art. The work by N.C. Wyeth was one of 16 illustrations made in 1929 for George Herbert Palmer's translation of Homer's "The Odyssey." Wyeth sold the series to a private collector...
Study Finds Pregnancy Nausea Drug Won't Harm Fetus
February 28, 2013 8:12 am | by MARILYNN MARCHIONE,AP Chief Medical Writer | News | CommentsThere's reassuring news for pregnant women miserable with morning sickness: A very large study in Denmark finds no evidence that using a popular anti-nausea drug will harm their babies. One in 10 pregnant women has nausea and vomiting bad enough to need medicine but many forgo it out of fear of side effects.
Kentucky Attorney General Sues GlaxoSmithKline
February 22, 2013 8:03 am | by BRUCE SCHREINER,Associated Press | News | CommentsKentucky's attorney general has joined in the flurry of legal action against GlaxoSmithKline, filing a lawsuit accusing the company of concealing the cardiovascular risks associated with a diabetes drug. The suit claims that GlaxoSmithKline LLC violated the state's Consumer Protection Act by overstating the effectiveness of the prescription drug Avandia and hiding its risks from consumers.
GSK and Theravance Announce FDA Acceptance of New Drug Application (NDA) Submission in the US for ANORO ELLIPTA(TM) for COPD
February 19, 2013 7:55 am | News | CommentsGlaxoSmithKline plc and Theravance, Inc. today announced that the New Drug Application (NDA) for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD), has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review.
In Philadelphia, Pharmaceutical Business Booms Where Battleships Were Born
February 11, 2013 8:22 am | by JOANN LOVIGLIO,Associated Press | News | CommentsThe city's Navy Yard, a massive military powerhouse where battleships were born until the Cold War put it on ice, is celebrating a milestone that seemed a stretch when the Navy shipped out 17 years ago. Once the nation's first shipyard — its origins date to 1776 — the sprawling property is now home to 130 companies and 10,000 employees in industries as varied as fashion, pharmaceuticals, colleges and cupcakes.
Europe Dents Glaxo's Q4 Profits
February 6, 2013 7:54 am | News | CommentsGlaxoSmithKline is looking to cut costs further this year as it reported a sharp drop in fourth-quarter profit on the back of problems in Europe. The company says Wednesday it made a net profit of 839 million pounds ($1.31 billion) in the final three months of 2012, down nearly 35 percent on the previous year. Over the year it made a profit of 4.74 billion pounds against 2011's 5.46 billion pounds.
GSK and Biological E. to Develop Combination Vaccine for India and Other Developing Countries
January 29, 2013 3:12 am | News | CommentsGlaxoSmithKline (GSK) and Biological E Limited (Biological E.), an Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage research and development of a six-in-one combination pediatric vaccine.
GSK appoints Hans Wijers to its Board as a Non-Executive Director
January 24, 2013 6:22 am | by GlaxoSmithKline | News | CommentsGlaxoSmithKline plc (LSE: GSK) today announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013.
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes
January 14, 2013 12:22 am | by GlaxoSmithKline | News | CommentsGlaxoSmithKline Enquiries: UK Media enquiries: David Mawdsley +44 (0) 20 8047 5502 (London) Sarah Spencer +44 (0) 20 8047 5502 (
GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe
January 9, 2013 3:21 am | by GlaxoSmithKline | News | CommentsGlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the European Union for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).
Galapagos Delivers Candidate Drug in GSK Alliance and Receives Milestone Payment
January 9, 2013 2:56 am | News | CommentsGalapagos NV announced today that it successfully delivered a fifth pre-clinical candidate drug in its alliance with GlaxoSmithKline (GSK) triggering a milestone payment to Galapagos.
Amicus Treatment for Fabry Disease Fails in Study
December 20, 2012 3:12 am | News | CommentsA potential treatment from Amicus Therapeutics and GlaxoSmithKline for Fabry disease, a rare disorder, missed its goals in late-stage testing, triggering a sell-off in Amicus' stock in after-hours trading.
GSK and Theravance announce regulatory submission for UMEC/VI (LAMA/LABA) in the US
December 19, 2012 6:22 pm | by GlaxoSmithKline | News | CommentsGlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline and Amicus Therapeutics announce top-line six-month primary treatment period results from first Phase III Fabry monotherapy study
December 19, 2012 6:22 pm | by GlaxoSmithKline | News | CommentsGlaxoSmithKline plc (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced the six-month primary treatment period results from the first Phase III global registration study (Study 011) of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had...
FDA Approves GSK's Four-Strain Seasonal Influenza Vaccine
December 18, 2012 4:22 am | News | CommentsGlaxoSmithKline has announced that the FDA has approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunization of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
GSK receives FDA approval for raxibacumab anti-toxin for the treatment of inhalational anthrax
December 14, 2012 12:21 pm | by GlaxoSmithKline | News | CommentsGlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for...
